Autoimmune Disease
Autoimmune Disease
复制标题
DOI：
10.1007/978-3-030-02278-5_91
复制
发表时间：
2019-01-01
期刊：
影响因子：
--
通讯作者：
Snowden, John A.
中科院分区：
文献类型：
--
作者：
Alexander, Tobias;Sharrack, Basil;Snowden, John A.
自身免疫性疾病 (AD) 是一组异质性疾病，影响着 8-10% 的西方人口，给社会带来沉重负担，并且常常使受影响的个人衰弱和致残。 AD 被定义为免疫系统受损，由于自身反应性 T 细胞和 B 细胞的存在以及跨遗传和环境因素的多因素病因学的复杂机制，导致对自身组织的免疫耐受性丧失（Alexander 和 Greco 2022）。自身免疫也与自身炎症有关，具有共同特征，即针对自身的激活，以及随后的全身炎症（第 93 章）。目前 AD 的治疗策略基于全身免疫抑制 (IS) 或靶向生物疾病缓解疗法 (DMT)，这些疗法可改善大多数患者的症状并阻止病情进展，但通常需要持续给药和
Autoimmune diseases (ADs) are a heterogeneous group of diseases affecting 8–10% of the Western population, which constitute a heavy burden to society and are often debilitating and disabling for affected individuals. ADs are defined as an impairment of the immune system resulting in the loss of immune tolerance against self-tissues, by the existence of autoreactive T and B cells and by a complex mechanism of multifactorial aetiology, across genetics and environmental factors (Alexander and Greco 2022). Autoimmunity is also linked to autoinflammation, having common features as the activation against self, with subsequent systemic inflammation (Chap. 93). Current therapeutic strategies for AD are based on systemic immunosuppression (IS) or targeted biologic disease-modifying therapies (DMTs), which ameliorate symptoms and halt progression in the vast majority of patients but usually require continuous administration and